Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.

Literature DB >> 25875052

Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.

Mikio Ohtsuka¹, Takako Miura¹, Tatsuhiko Mori¹, Masato Ishikawa¹, Toshiyuki Yamamoto¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 25875052 DOI： 10.1001/jamadermatol.2015.0249

Source DB: PubMed Journal: JAMA Dermatol ISSN： 2168-6068 Impact factor: 10.282

Keyword Cloud
Cited

× No keyword cloud information.

27 in total

Review 1. Cutaneous toxicities of new treatments for melanoma.

Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405

Review 2. Checkpoint Inhibitors.

Authors: Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal: Dtsch Arztebl Int Date: 2019-02-22 Impact factor: 5.594

3. Ranolazine-Induced Reversible T-Wave Inversions with Prolonged QTc Interval; Progressive Multifocal Leukoencephalopathy Linked to Fingolimod; Losartan-Induced Sprue-like Enteropathy; Nivolumab-Induced Psoriasiform Skin Eruption; Hepatitis B Reactivation with Hepatitis C Treatment with Simeprevir and Sofosbuvir.

Authors: Michael A Mancano
Journal: Hosp Pharm Date: 2015-11-24

Review 4. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

5. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Authors: Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube
Journal: Am J Surg Pathol Date: 2017-10 Impact factor: 6.394

Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.

Review 1. Cutaneous toxicities of new treatments for melanoma.

Review 2. Checkpoint Inhibitors.

Review 4. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

5. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

6. Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis.

Review 7. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Review 8. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Review 9. Immune checkpoint inhibitor-related dermatologic adverse events.

10. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.